Abstract
The complex neurodevelopmental disorder schizophrenia is thought to be induced by an interaction between predisposing genes and environmental stressors. In order to get a better insight into the aetiology of this complex disorder, animal models have been developed. In this review, we summarize mRNA expression profiling studies on neurodevelopmental, pharmacological and genetic animal models for schizophrenia. We discuss parallels and contradictions among these studies, and propose strategies for future research.
Keywords: Animal model, behavior, genetics, microarray, mRNA expression, neurodevelopment, pharmacology, Gene Expression, Rodent Models, Schizophrenia, delusions, hallucinations, ganized speech, grossly disorganized, catatonic behaviour, negative symptoms, neuregulin-1, transferase, hyperlocomotion, social withdrawal, loss of prepulse, cognitive deficits, serotonin, Affymetrix, quantitative polymerase chain reaction, astrocytes, hippocampus, cytokine, apoptosis, calcium/calmodulin signaling, neurotransmitter, VH lesions, haloperidol, mitochondrial cytochrome, oxidase, chondrial tRNA, isoforms, adenosine, transthyretin, glutamate, substances, phencyclidine, prefrontal cortex, Leiomodin 2, ketamine, cyclo-oxygenase, NMDA receptor, MK-801
Current Neuropharmacology
Title: Gene Expression Profiling in Rodent Models for Schizophrenia
Volume: 8 Issue: 4
Author(s): Jessica E. Van Schijndel and Gerard J.M. Martens
Affiliation:
Keywords: Animal model, behavior, genetics, microarray, mRNA expression, neurodevelopment, pharmacology, Gene Expression, Rodent Models, Schizophrenia, delusions, hallucinations, ganized speech, grossly disorganized, catatonic behaviour, negative symptoms, neuregulin-1, transferase, hyperlocomotion, social withdrawal, loss of prepulse, cognitive deficits, serotonin, Affymetrix, quantitative polymerase chain reaction, astrocytes, hippocampus, cytokine, apoptosis, calcium/calmodulin signaling, neurotransmitter, VH lesions, haloperidol, mitochondrial cytochrome, oxidase, chondrial tRNA, isoforms, adenosine, transthyretin, glutamate, substances, phencyclidine, prefrontal cortex, Leiomodin 2, ketamine, cyclo-oxygenase, NMDA receptor, MK-801
Abstract: The complex neurodevelopmental disorder schizophrenia is thought to be induced by an interaction between predisposing genes and environmental stressors. In order to get a better insight into the aetiology of this complex disorder, animal models have been developed. In this review, we summarize mRNA expression profiling studies on neurodevelopmental, pharmacological and genetic animal models for schizophrenia. We discuss parallels and contradictions among these studies, and propose strategies for future research.
Export Options
About this article
Cite this article as:
E. Van Schijndel Jessica and J.M. Martens Gerard, Gene Expression Profiling in Rodent Models for Schizophrenia, Current Neuropharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157015910793358132
DOI https://dx.doi.org/10.2174/157015910793358132 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Acute Myeloid Leukemia in the Elderly: Current Therapeutic Results and Perspectives for Clinical Research
Reviews on Recent Clinical Trials Perspectives in Nanomedicine-Based Research Towards Cancer Therapies
Current Nanoscience Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry A Structure-Function Perspective of Jak2 Mutations and Implications for Alternate Drug Design Strategies: The Road not Taken
Current Medicinal Chemistry Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Infectious Disorders - Drug Targets New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry Novel Drug Targets in Malaria Parasite with Potential to Yield Antimalarial Drugs with Long Useful Therapeutic Lives
Current Pharmaceutical Design The Metabolomic Strategy in Tuberculosis Therapy
Combinatorial Chemistry & High Throughput Screening CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia
Current Cancer Drug Targets Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response
Current Molecular Medicine Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Current Drug Targets Going 3D – Cell Culture Approaches for Stem Cell Research and Therapy
Current Tissue Engineering (Discontinued) Application of Artificial Neural Networks for the Prediction of Antitumor Activity of a Series of Acridinone Derivatives
Medicinal Chemistry Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Current Pharmaceutical Design